Concert Pharmaceuticals is in patent battle with Incyte Corporation over CTP-543, which is deuterated Ruxolitinib. Ruxolitinib is owned by Incyte Corporation and is FDA approved for certain cancer indications such as myelofibrosis. The transcripts of the patent hearing that took place in January is here hearing - transcript. The verdict will be announced in April. After reading the transcripts, I believe the counsel for Concert did well enough in the patent dispute to win, which will allow the company to advance CTP-543 forward for auto-immune indications such as Alopecia Areata. If by chance the ruling falls against Concert Pharmaceuticals, then the company has already stated that it will advance the patent dispute to circuit court. Thank you for reading.
